SurModics, Inc. (SRDX)
| Market Cap | 494.97M |
| Revenue (ttm) | 96.95M |
| Net Income (ttm) | -10.47M |
| Shares Out | 13.99M |
| EPS (ttm) | -0.76 |
| PE Ratio | n/a |
| Forward PE | 34.36 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 33,269 |
| Open | 35.59 |
| Previous Close | 35.91 |
| Day's Range | 35.01 - 36.85 |
| 52-Week Range | 32.43 - 62.27 |
| Beta | 1.02 |
| Analysts | Buy |
| Price Target | 75.48 (+113.3%) |
| Earnings Date | Apr 27, 2022 |
About SRDX
Surmodics, Inc., together with its subsidiaries, provides surface modification technologies for intravascular medical devices, and chemical components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates in two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to pr...
Financial Performance
In 2021, SurModics's revenue was $105.14 million, an increase of 10.83% compared to the previous year's $94.86 million. Earnings were $4.24 million, an increase of 277.29%.
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for SRDX stock is "Buy." The 12-month stock price forecast is 75.48, which is an increase of 113.34% from the latest price.
News
Surmodics (SRDX) Beats on Q2 Earnings, Revises FY22 View
Despite solid IVD revenues, Surmodics (SRDX) reports a soft Q2 overall top line.
SurModics (SRDX) Reports Q2 Loss, Tops Revenue Estimates
SurModics (SRDX) delivered earnings and revenue surprises of 31.25% and 6.99%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Surmodics Reports Second Quarter Fiscal 2022 Results
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics Reports Second Quarter Fiscal 2022 Results
Dr. Gary Ansel to Present Pounce™ Thrombectomy System First-in-Human Data at Charing Cross Symposium
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Dr. Gary Ansel to Present Pounce™ Thrombectomy System First-in-Human Data at Charing Cross Symposium
Surmodics to Webcast Second Quarter Fiscal 2022 Earnings Conference Call on April 27
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics to Webcast Second Quarter Fiscal 2022 Earnings Conference Call on April 27.
Reasons to Add Surmodics (SRDX) Stock to Your Portfolio
Investors continue to be optimistic about Surmodics (SRDX) owing to its consistent efforts to boost R&D.
Surmodics to Host Virtual Annual Meeting of Shareholders
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics to Host Virtual Annual Meeting of Shareholders on February 10, 2022 at 4:00 p.m. (CT)
SurModics (SRDX) Reports Q1 Loss, Misses Revenue Estimates
SurModics (SRDX) delivered earnings and revenue surprises of 63.89% and 3.47%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Surmodics Reports First Quarter Fiscal 2022 Results
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics Reports First Quarter Fiscal 2022 Results
Analysts Estimate SurModics (SRDX) to Report a Decline in Earnings: What to Look Out for
SurModics (SRDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Surmodics to Webcast First Quarter Fiscal 2022 Earnings Conference Call on February 3
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #Catheter--Surmodics to Webcast First Quarter Fiscal 2022 Earnings Conference Call on February 3. Webcast is Live at 7:30 a.m. (CT)
Surmodics to Present at Sidoti & Company Virtual Investor Conference
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics to Present at Sidoti & Company Virtual Investor Conference on January 19, 2022.
Surmodics (SRDX) Stock Loses 2.2% Despite Q4 Earnings Beat
Surmodics' (SRDX) fiscal fourth-quarter results reflect benefits from segmental strength.
SurModics (SRDX) Reports Q4 Loss, Tops Revenue Estimates
SurModics (SRDX) delivered earnings and revenue surprises of 60.00% and 6.73%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Surmodics Reports Fourth Quarter Fiscal 2021 Results and Issues Fiscal 2022 Revenue and EPS Guidance
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics Reports Fourth Quarter Fiscal 2021 Results and Issues Fiscal 2022 Revenue and EPS Guidance
Surmodics to Webcast Fourth Quarter Fiscal 2021 Earnings Conference Call on November 10
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics to Webcast Fourth Quarter Fiscal 2021 Earnings Conference Call on November 10. Webcast is Live at 7:30 a.m. (CT)
Surmodics' (SRDX) Latest Sublime Catheter Expands Patient Pool
Surmodics' (SRDX) latest addition is expected to aid in performing more complex interventions which were earlier not possible.
Surmodics Announces Successful First Patient Uses of Sublime™ Radial Access .018 RX PTA Dilatation Catheter
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics Announces Successful First Patient Uses of Sublime™ Radial Access .018 RX PTA Dilatation Catheter
HRC vs. SRDX: Which Stock Is the Better Value Option?
HRC vs. SRDX: Which Stock Is the Better Value Option?
Surmodics' (SRDX) Q3 Earnings, Revenues Fall Shy of Estimates
Higher revenues from the IVD segment drives Surmodics' (SRDX) fiscal third-quarter top line.
SurModics (SRDX) Reports Q3 Loss, Misses Revenue Estimates
SurModics (SRDX) delivered earnings and revenue surprises of -54.55% and -0.32%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Recap: Surmodics Q3 Earnings
Shares of Surmodics (NASDAQ:SRDX) remained unaffected after the company reported Q3 results. Quarterly Results Earnings per share fell 180.95% year over year to ($0.17), which were in line with the esti...
Surmodics Reports Third Quarter Fiscal 2021 Results and Updates Fiscal 2021 Revenue and EPS Guidance
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #IVD--Surmodics Reports Third Quarter Fiscal 2021 Results and Updates Fiscal 2021 Revenue and EPS Guidance
Surmodics Announces Successful First Patient Use of Pounce™ Thrombectomy System
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #510K--Surmodics Announces Successful First Patient Use of Pounce™ Thrombectomy System
Earnings Preview: SurModics (SRDX) Q3 Earnings Expected to Decline
SurModics (SRDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.